WO2003033507A1 - Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant - Google Patents

Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant Download PDF

Info

Publication number
WO2003033507A1
WO2003033507A1 PCT/JP2002/010451 JP0210451W WO03033507A1 WO 2003033507 A1 WO2003033507 A1 WO 2003033507A1 JP 0210451 W JP0210451 W JP 0210451W WO 03033507 A1 WO03033507 A1 WO 03033507A1
Authority
WO
WIPO (PCT)
Prior art keywords
remedies
acid derivatives
alkyl
diseases
contaiing
Prior art date
Application number
PCT/JP2002/010451
Other languages
English (en)
Japanese (ja)
Inventor
Hiroaki Satoh
Yoji Tachibana
Koichi Nakamaru
Ryotaro Kojima
Original Assignee
Kyorin Pharmaceutical Co., Ltd.
Nisshin Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co., Ltd., Nisshin Pharma Inc. filed Critical Kyorin Pharmaceutical Co., Ltd.
Priority to JP2003536246A priority Critical patent/JPWO2003033507A1/ja
Publication of WO2003033507A1 publication Critical patent/WO2003033507A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des dérivés d'acide benzylmalonique, présentant un effet inhibiteur de protéasomes, représentés par la formule générale suivante (I), où X représente N ou CH ; et R représente hydrogène, alkyle C1-6, cycloalkyle C3-7, alkyle C1-6 phényle ou alkyle C1-6 cycloalkyle C3-6. Lesdits composés, qui inhibent de manière sélective les immunoprotéasomes mais inhibent difficilement les protéasomes constitutifs, sont utiles en tant qu'immunosuppresseurs, agents anti-inflammatoires, agents antiallergiques, remèdes contre les maladies auto-immunes, remèdes contre les maladies inflammatoires chroniques telles que les maladies entériques inflammatoires (colite ulcéreuse, maladie de Crohn), agents anticancéreux et remèdes contre les maladies neurodégénératives.
PCT/JP2002/010451 2001-10-12 2002-10-08 Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant WO2003033507A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003536246A JPWO2003033507A1 (ja) 2001-10-12 2002-10-08 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001314732 2001-10-12
JP2001-314732 2001-10-12

Publications (1)

Publication Number Publication Date
WO2003033507A1 true WO2003033507A1 (fr) 2003-04-24

Family

ID=19132996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/010451 WO2003033507A1 (fr) 2001-10-12 2002-10-08 Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant

Country Status (2)

Country Link
JP (1) JPWO2003033507A1 (fr)
WO (1) WO2003033507A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021558A2 (fr) * 2003-08-14 2005-03-10 Cephalon, Inc. Inhibiteurs de proteasomes et procedes d'utilisation de ceux-ci
EP2088205A1 (fr) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10 : marqueur de diagnostic et cible thérapeutique de rejet chronique
EP2377868A1 (fr) 2004-03-30 2011-10-19 Millennium Pharmaceuticals, Inc. Synthèse de Bortezomib
US8283367B2 (en) 2005-02-11 2012-10-09 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US8513218B2 (en) 2010-03-31 2013-08-20 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
US8530694B2 (en) 2007-08-06 2013-09-10 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US8541590B2 (en) 2009-12-22 2013-09-24 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
US8664200B2 (en) 2008-09-29 2014-03-04 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclobutylethylboronic acid
US8859504B2 (en) 2008-06-17 2014-10-14 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
US11241448B2 (en) 2014-05-20 2022-02-08 Millennium Pharmaceuticals, Inc. Methods for cancer therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013266A1 (fr) * 1994-10-28 1996-05-09 Proscript, Inc. Composes d'esters et d'acides boroniques, leur synthese et leurs utilisations
US5814622A (en) * 1996-02-27 1998-09-29 Adir Et Compagnie Compounds derived from boronic acid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013266A1 (fr) * 1994-10-28 1996-05-09 Proscript, Inc. Composes d'esters et d'acides boroniques, leur synthese et leurs utilisations
US5814622A (en) * 1996-02-27 1998-09-29 Adir Et Compagnie Compounds derived from boronic acid

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9233115B2 (en) 2003-08-14 2016-01-12 Millennium Pharmaceuticals Inc. Proteasome inhibitors and methods of using the same
JP4917431B2 (ja) * 2003-08-14 2012-04-18 セファロン、インク． プロテアソーム阻害剤及びそれらを使用する方法
JP2007502304A (ja) * 2003-08-14 2007-02-08 セファロン、インク． プロテアソーム阻害剤及びそれらを使用する方法
EA010804B1 (ru) * 2003-08-14 2008-12-30 Сефэлон, Инк. ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ ПРОТЕАСОМ, СПОСОБЫ ИНГИБИРОВАНИЯ АКТИВНОСТИ ПРОТЕАСОМЫ, ФАКТОРА ТРАНСКРИПЦИИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБ ЛЕЧЕНИЯ РАКА
US7915236B2 (en) 2003-08-14 2011-03-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US8546608B2 (en) 2003-08-14 2013-10-01 Cephalon, Inc. Proteasome inhibitors and methods of using the same
WO2005021558A3 (fr) * 2003-08-14 2005-05-12 Cephalon Inc Inhibiteurs de proteasomes et procedes d'utilisation de ceux-ci
US8058262B2 (en) 2003-08-14 2011-11-15 Cephalon, Inc. Proteasome inhibitors and methods of using the same
WO2005021558A2 (fr) * 2003-08-14 2005-03-10 Cephalon, Inc. Inhibiteurs de proteasomes et procedes d'utilisation de ceux-ci
CN107474062A (zh) * 2004-03-30 2017-12-15 千禧药品公司 硼的酯和酸化合物的合成
EP2377868A1 (fr) 2004-03-30 2011-10-19 Millennium Pharmaceuticals, Inc. Synthèse de Bortezomib
US8283367B2 (en) 2005-02-11 2012-10-09 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US8530694B2 (en) 2007-08-06 2013-09-10 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US8772536B2 (en) 2007-08-06 2014-07-08 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US8871745B2 (en) 2007-08-06 2014-10-28 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
EP2088205A1 (fr) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10 : marqueur de diagnostic et cible thérapeutique de rejet chronique
US10604538B2 (en) 2008-06-17 2020-03-31 Millenium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
US11485746B2 (en) 2008-06-17 2022-11-01 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
US10526351B2 (en) 2008-06-17 2020-01-07 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
US9175018B2 (en) 2008-06-17 2015-11-03 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
US9175017B2 (en) 2008-06-17 2015-11-03 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
US8859504B2 (en) 2008-06-17 2014-10-14 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
US10035811B2 (en) 2008-09-29 2018-07-31 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclobutylethylboronic acid
US8664200B2 (en) 2008-09-29 2014-03-04 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclobutylethylboronic acid
US9771381B2 (en) 2008-09-29 2017-09-26 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclobutylethylboronic acid
US8541590B2 (en) 2009-12-22 2013-09-24 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
US8513218B2 (en) 2010-03-31 2013-08-20 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
US9023832B2 (en) 2010-03-31 2015-05-05 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
US8703743B2 (en) 2010-03-31 2014-04-22 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
US11241448B2 (en) 2014-05-20 2022-02-08 Millennium Pharmaceuticals, Inc. Methods for cancer therapy

Also Published As

Publication number Publication date
JPWO2003033507A1 (ja) 2005-02-03

Similar Documents

Publication Publication Date Title
WO2003033507A1 (fr) Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant
WO2009020140A1 (fr) Dérivé d'adamantylurée
WO2007084415A3 (fr) Composes pour le traitement de troubles inflammatoires
WO2008083248A3 (fr) Analogues de cyclopamine
WO2008092954A8 (fr) Formes polymorphes d'un inhibiteur macrocyclique de hcv
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
WO2009031642A1 (fr) Composition pharmaceutique
WO2005121130A3 (fr) Composes pour le traitement de troubles inflammatoires
MXPA05009985A (es) Ligandos de receptores de canabinoides.
TW200738688A (en) Compounds for the treatment of inflammatory disorders
WO2006123113A3 (fr) Composes chimiques
WO2007014054A3 (fr) Inhibiteur benzenesulfonamide de recepteur de chimiokine ccr2
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
MX2009004019A (es) Compuestos heteroarilo, composiciones de los mismos, y uso de los mismos como inhibidores de proteina cinasa.
NO20092723L (no) Indazolylester og amidderivater for behandling av gluccocorticoid reseptormedierte sykdommer
WO2007148185A3 (fr) 3-amino-pyrrolidino-4-lactames substitués
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
WO2008108386A1 (fr) Composition pharmaceutique
NO20091265L (no) Pyrrolopyrazin som Syk-kinase inhibitor
DK1888080T3 (da) Farmaceutiske sammensætninger af en neuroaktiv steroid og anvendelser deraf
WO2008153159A1 (fr) Composé aminé et son utilisation pharmaceutique
SE0400284D0 (sv) Novel compounds
WO2008012338A3 (fr) Nouvelles formulations
WO2005037205A3 (fr) Composes substitues par haloacetamide et azide, et methodes d'utilisation des composes
CA2585802A1 (fr) Procede industriel de synthese de la .gamma.-lactone de l'acide 17-hydroxy-6.beta.,7.beta.;15.beta.,16.beta.-bismethylene-3-oxo-17.alpha.-pregn-4-ene-21-carboxylique et intermediaires-cles de ce procede

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003536246

Country of ref document: JP

122 Ep: pct application non-entry in european phase